MBX Biosciences reported Phase 2a proof-of-concept data ↗ for once-weekly imapextide in post-bariatric hypoglycemia on May 11, with the STEADI trial showing glucose nadir increases of 17 to 34 percent and insulin peak reductions of 11 to 45 percent across the tested doses. The drug works the same way Amylyx's avexitide ↗ does, blocking the GLP-1 receptor on pancreatic islet beta-cells to blunt the inappropriate post-meal insulin surge that drives PBH. The clinical signal is real and the indication is exactly the same as the one Amylyx's avexitide is racing into Phase 3 LUCIDITY readout for in the third quarter of 2026. The avexitide commercial picture, which the news section described 24 hours ago as a first-in-class niche, is now a two-drug race.
Imapextide is MBX Biosciences's once-weekly GLP-1 receptor antagonist peptide. The STEADI Phase 2a trial reads in numbers patients and clinicians actually use: glucose nadir is the lowest blood sugar level a patient hits in the hour or two after a meal (the metric that drives PBH symptoms), and insulin peak is how much insulin the pancreas dumps in response to the meal (the upstream driver of the nadir). Raising the nadir 17 to 34 percent across doses moves patients away from the symptomatic range where shaking, sweating, and loss-of-consciousness episodes occur. Cutting the insulin peak 11 to 45 percent attenuates the cause directly. Both effects scale with dose in the predictable way Phase 2a expects of a mechanism-active drug, which is the regulatory definition of proof of concept.
The Amylyx comparison matters because the two drugs are mechanistically similar but practically different. Avexitide is exendin (9-39), the 31-amino-acid truncated form of exendin-4 administered subcutaneously, with Phase 3 LUCIDITY topline expected in Q3 2026 and a 250-patient US Expanded Access Program running in parallel. Imapextide is a separate peptide architecture from MBX (the company has not disclosed the full sequence publicly), engineered for once-weekly subcutaneous dosing, currently at the end of Phase 2a with the timeline to Phase 3 still to be specified. The commercial implication is the standard second-mover dynamic. Avexitide is closer to market and carries FDA Breakthrough Therapy Designation; imapextide arrives behind it but with potentially better dosing convenience (once-weekly vs avexitide's currently-disclosed subcutaneous regimen) and time to read out longer-duration data. The two-drug race in PBH validates the mechanism more than it threatens either program. PBH is a small market in absolute terms (tens of thousands of US patients), and two approved drugs in a small population usually means market segmentation by patient subtype rather than head-to-head price competition.
The same May 11 announcement covered two other MBX programs. MBX 4291, a GLP-1 receptor agonist GIP receptor agonist co-agonist prodrug, posted preliminary Phase 1 MAD Part B data showing an apparent terminal half-life around 26 days, consistent with true once-monthly subcutaneous dosing. The 12-week Phase 1 MAD Part C readout is guided for the fourth quarter of 2026. MBX 4291 sits in the same dual-agonist mechanism class as tirzepatide ↗ (Mounjaro ↗/Zepbound ↗), but the prodrug architecture is engineered for monthly rather than weekly delivery, which would be a meaningful dosing-frequency advance over the entire current GLP-1 class. MBX 5765, newly nominated as an IND-enabling candidate for Q2 2026, combines GLP-1, GIP, glucagon, and DACRA (dual amylin and calcitonin receptor agonist) activity in a single peptide construct, also engineered for once-monthly delivery. Four-receptor agonism converging into one molecule is the next step beyond the triple-agonist class that retatrutide ↗ anchors and the Lilly quintuple-agonist program previewed for ADA 2026 represents at the experimental edge.
The dosing-frequency arc is worth holding carefully. The first generation of GLP-1 peptides (exenatide, liraglutide ↗) was twice-daily or daily. The second generation (semaglutide ↗, tirzepatide) is once-weekly. MBX is now claiming Phase 1 evidence for true once-monthly peptide dosing on two of its three programs. Once-monthly subcutaneous dosing for an obesity peptide would change patient experience meaningfully (twelve injections per year vs fifty-two), reduce the activation energy of staying on therapy, and likely improve real-world adherence, which is the dominant determinant of real-world weight loss in this drug class. Ascletis's ECO 2026 slate includes parallel once-monthly claims on its own ASC36 amylin program and ASC35 dual GLP-1R/GIPR program, with 32-day and 14-day average half-lives respectively. The dosing-frequency competition in obesity peptides has shifted from weekly versus daily to monthly versus weekly, and the engineering question is whether the peptide PK can hold the receptor occupancy needed for sustained weight loss over the longer dosing interval without losing efficacy at trough.
What this changes for the platform. PBH peptide antagonists become a small but real corner of the peptide drug space rather than a single-drug curiosity. The GLP-1 receptor's clinical relevance now extends across both directions of receptor activity (agonism for the broad metabolic-disease class, antagonism for PBH and congenital hyperinsulinism), with two distinct drug architectures racing through Phase 2a and Phase 3 in the same niche indication. The dosing-frequency arc on the obesity side is moving toward monthly, and Phase 1 pharmacokinetic data on multiple programs is the leading indicator that the upcoming wave of GLP-1 peptides will compete on dosing convenience as much as on weight-loss efficacy.
What this is not. A direct head-to-head readout. Imapextide STEADI and avexitide LUCIDITY are separate trials with overlapping endpoints but non-identical primary outcomes and non-identical patient populations, and a head-to-head trial does not yet exist. What this is is enough evidence to say that the PBH indication has two viable peptide programs in late-stage development, that the GLP-1 receptor antagonist mechanism has been validated by Phase 2a clinical data outside Amylyx's own program, and that the obesity-peptide dosing-frequency window is starting to move from weekly toward monthly in a way that will reshape the standard of care over the next clinical-cycle generation.